search
Back to results

Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

Primary Purpose

Chronic Heart Failure

Status
Terminated
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
rhNRG-1
Placebo
Sponsored by
Zensun Sci. & Tech. Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Heart Failure focused on measuring Chronic Heart Failure, rhNRG-1, NT-proBNP

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age between 18 and 75, both sex.
  2. Left ventricular ejection fraction (LVEF)≤40% (ECHO).
  3. NYNA functional class II~III.
  4. Definitely diagnosed with chronic systolic heart failure (including medical records, symptoms and physical signs)and clinical symptom is steadily in the latest 1 month.
  5. Receiving standard basic treatment of heart failure, has reached the objective dosage or the highest tolerated dosage for at least 1 month, or the dosage has not been changed for at least 1 month.
  6. Capable of signing the informed consent form.

Exclusion Criteria:

  1. Patients with acute myocardial infarction, Hypertrophic cardiomyopathy, constrictive pericarditis, significant valvular pathological change or congenital heart diseases, severe pulmonary artery hypertension.
  2. Ischemic heart failure without recanalization or with recanalization in recent six months.
  3. Cardiac surgery or cerebrovascular accident within recent six months.
  4. Preparing for heart transplantation or has received CRT treatment.
  5. Serious hepatic or renal dysfunction caused by organic pathological changes (Cr>2.0mg/dl, AST or ALT 5 times above the normal upper limit).
  6. Patients need mechanical ventilation.
  7. Systolic blood pressure <90mmHg or >160mmHg.
  8. Patients with acute hemodynamic disorder or decompensation in the last 1 month.
  9. Serious ventricular arrhythmia (multi-morphological premature ventricular contraction, frequent paroxysmal ventricular tachycardia).
  10. Serum potassium <3.2 mmol/L or >5.5 mmol/L.
  11. Pregnant or plan to pregnant.
  12. Unmarried or married but not procreated women at child-bearing age.
  13. Subject with a life expectancy less than 6 months as assessed by the investigator.
  14. Patients who participated in any clinical trial in the recent three months.
  15. History of any malignancy or suffering from cancer,or biopsy proven pre-malignant condition (eg DICS or cervical atypia).
  16. Evidence (physical examination,CXR,ECHO or other tests) shows some active malignancy or adenoidal hypertrophy or neoplasm has effect on heart function or endocrine system, eg pheochromocytoma or hyperthyroidism.
  17. Judging by the investigator, the patients could not complete the study or adhere to the study requirements (due to the management reasons or others).

Sites / Locations

  • Cardiovascular Institute and Fuwai Hospital
  • Bethune Peace Hospital
  • Teda International Cardiovascular Hospital
  • Daqing Oilfield General Hospital
  • The First Hospital of Harbin Medical University
  • The First Affiliated Hospital of Zhengzhou University
  • The Second Xiangya Hospital of Central South University
  • Sichuan Provincial People's Hospital
  • The Second Hospital affiliated to Suzhou University
  • North Jiangsu People's Hospital
  • The Affiliate Hospital of Jiangsu University
  • The Second Hospital of Jilin University
  • The First Hospital affiliated to Dalian Medical University
  • The first affiliated hospital of Liaoning medical college
  • Liaoning Provincial People's Hospital
  • Shengjing Hospital of China Medical University
  • Qilu Hospital of Shandong University
  • Shanghai First People's Hospital
  • Shanghai Sixth People's Hospital
  • The Xinqiao Hospital of Third Military Medical University
  • Kunming General Hospital of Chengdu Military Region

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

rhNRG-1

Plaebo

Arm Description

Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure

Excipient placebo in addition to basic therapy of chronic heart failure

Outcomes

Primary Outcome Measures

NT-proBNP

Secondary Outcome Measures

NT-proBNP
Six Minutes Walk Distance
NYHA classification
Quality of Life

Full Information

First Posted
September 21, 2011
Last Updated
December 19, 2017
Sponsor
Zensun Sci. & Tech. Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01439789
Brief Title
Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
Official Title
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Terminated
Why Stopped
Sponsor has designed another study with different endpoint to replace the current study
Study Start Date
June 2011 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zensun Sci. & Tech. Co., Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on serum NT-proBNP, as well as safety in patients with chronic heart failure.
Detailed Description
N-terminal proNBP (NT-proBNP) has been proved to be an independent prognostic factor for the long-term prognosis of chronic heart failure patients.RhNRG-1(recombinant human neuregulin-1)directly works on the cardiomyocytes and restored the normal structure and function of it. It has been found that rhNRG-1 effectively decreased the serum level of NT-proBNP,and is tolerated in the effective dosages groups.The aim of this phase III trial is to further confirm in large population that rhRNG-1 administration can effectively decrease the serum level of NT-proBNP and is tolerated in patients with chronic heart failure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Heart Failure
Keywords
Chronic Heart Failure, rhNRG-1, NT-proBNP

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
146 (Actual)

8. Arms, Groups, and Interventions

Arm Title
rhNRG-1
Arm Type
Active Comparator
Arm Description
Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
Arm Title
Plaebo
Arm Type
Placebo Comparator
Arm Description
Excipient placebo in addition to basic therapy of chronic heart failure
Intervention Type
Drug
Intervention Name(s)
rhNRG-1
Intervention Description
day1~day10:0.6ug/kg/day,10hours per day for vein infusion
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
day1~day10:0.6ug/kg/day,10hours per day for vein infusion
Primary Outcome Measure Information:
Title
NT-proBNP
Time Frame
30 days
Secondary Outcome Measure Information:
Title
NT-proBNP
Time Frame
90 days
Title
Six Minutes Walk Distance
Time Frame
30 days and 90 days
Title
NYHA classification
Time Frame
30 days and 90 days
Title
Quality of Life
Time Frame
30 days and 90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18 and 75, both sex. Left ventricular ejection fraction (LVEF)≤40% (ECHO). NYNA functional class II~III. Definitely diagnosed with chronic systolic heart failure (including medical records, symptoms and physical signs)and clinical symptom is steadily in the latest 1 month. Receiving standard basic treatment of heart failure, has reached the objective dosage or the highest tolerated dosage for at least 1 month, or the dosage has not been changed for at least 1 month. Capable of signing the informed consent form. Exclusion Criteria: Patients with acute myocardial infarction, Hypertrophic cardiomyopathy, constrictive pericarditis, significant valvular pathological change or congenital heart diseases, severe pulmonary artery hypertension. Ischemic heart failure without recanalization or with recanalization in recent six months. Cardiac surgery or cerebrovascular accident within recent six months. Preparing for heart transplantation or has received CRT treatment. Serious hepatic or renal dysfunction caused by organic pathological changes (Cr>2.0mg/dl, AST or ALT 5 times above the normal upper limit). Patients need mechanical ventilation. Systolic blood pressure <90mmHg or >160mmHg. Patients with acute hemodynamic disorder or decompensation in the last 1 month. Serious ventricular arrhythmia (multi-morphological premature ventricular contraction, frequent paroxysmal ventricular tachycardia). Serum potassium <3.2 mmol/L or >5.5 mmol/L. Pregnant or plan to pregnant. Unmarried or married but not procreated women at child-bearing age. Subject with a life expectancy less than 6 months as assessed by the investigator. Patients who participated in any clinical trial in the recent three months. History of any malignancy or suffering from cancer,or biopsy proven pre-malignant condition (eg DICS or cervical atypia). Evidence (physical examination,CXR,ECHO or other tests) shows some active malignancy or adenoidal hypertrophy or neoplasm has effect on heart function or endocrine system, eg pheochromocytoma or hyperthyroidism. Judging by the investigator, the patients could not complete the study or adhere to the study requirements (due to the management reasons or others).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Runlin Gao, MD, Ph.D
Organizational Affiliation
Cardiovascular Institute and Fuwai Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiovascular Institute and Fuwai Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Bethune Peace Hospital
City
Shijiazhuang
State/Province
Hebei
Country
China
Facility Name
Teda International Cardiovascular Hospital
City
Tianjin
State/Province
Hebei
Country
China
Facility Name
Daqing Oilfield General Hospital
City
Daqing
State/Province
Heilongjiang
Country
China
Facility Name
The First Hospital of Harbin Medical University
City
Haerbin
State/Province
Heilongjiang
Country
China
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
Country
China
Facility Name
The Second Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
Country
China
Facility Name
Sichuan Provincial People's Hospital
City
Chengdu
State/Province
Jiangsu
Country
China
Facility Name
The Second Hospital affiliated to Suzhou University
City
Suzhou
State/Province
Jiangsu
Country
China
Facility Name
North Jiangsu People's Hospital
City
Yangzhou
State/Province
Jiangsu
Country
China
Facility Name
The Affiliate Hospital of Jiangsu University
City
Zhenjiang
State/Province
Jiangsu
Country
China
Facility Name
The Second Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Facility Name
The First Hospital affiliated to Dalian Medical University
City
Dalian
State/Province
Liaoning
Country
China
Facility Name
The first affiliated hospital of Liaoning medical college
City
Jinzhou
State/Province
Liaoning
Country
China
Facility Name
Liaoning Provincial People's Hospital
City
Shenyang
State/Province
Liaoning
Country
China
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
Country
China
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
Country
China
Facility Name
Shanghai First People's Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
Shanghai Sixth People's Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
The Xinqiao Hospital of Third Military Medical University
City
Chongqing
State/Province
Sichuan
Country
China
Facility Name
Kunming General Hospital of Chengdu Military Region
City
Kunming
State/Province
Yunnan
Country
China

12. IPD Sharing Statement

Learn more about this trial

Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

We'll reach out to this number within 24 hrs